TMED1 Activators
TMED1 activators are compounds that, through various mechanisms, may support the functional activity or expression of the transmembrane emp24 domain-containing protein 1 (TMED1). This protein plays a pivotal role in vesicular protein trafficking, particularly within the early secretory pathway, and has implications in the modulation of immune signaling. The activators identified operate within intersecting biochemical pathways or influence cellular processes that could result in the upregulation of TMED1's activity. For instance, molecules like cyclic GMP-AMP, which is involved in the cGAS-STING pathway-a pathway with which TMED1 is associated-can enhance the innate immune response, possibly necessitating an increased functional demand on TMED1.
Furthermore, this chemical class includes molecules such as Zinc pyrithione and STING agonists that are known to stimulate immune pathways in which TMED1 has been implicated, possibly augmenting its activity indirectly. Agents like Ruxolitinib and Anakinra, which modulate cytokine signaling, could indirectly influence the activity of TMED1 by altering the inflammatory milieu. Additionally, compounds like U18666A affect cholesterol transport and thus the lipid environments of cellular organelles, which could impinge on TMED1's trafficking capabilities
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
25-Hydroxycholesterol | 2140-46-7 | sc-214091B sc-214091 sc-214091A sc-214091C | 5 mg 10 mg 25 mg 100 mg | $53.00 $91.00 $169.00 $474.00 | 8 | |
Oxysterol that can modulate lipid metabolism and has been reported to influence vesicular trafficking pathways. | ||||||
2′,3′-cGAMP | 1441190-66-4 | sc-507484 | 10 mg | $1800.00 | ||
Endogenous second messenger in the cGAS-STING pathway, which TMED1 might influence through its interaction with RNF26. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Can stimulate the STING pathway, potentially enhancing the role of TMED1 in this immune response if TMED1's interaction with RNF26 is positively involved in STING regulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor that may alter cytokine signaling pathways and could affect TMED1's role in IL-33-mediated responses indirectly. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
IL-1 receptor antagonist that may influence IL-33 signaling and indirectly modulate TMED1 function. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
Cholesterol transport inhibitor which may influence the lipid environment of the ER and Golgi, potentially affecting TMED1's function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BRD4 inhibitor that has implications on various signaling pathways, including inflammatory responses, and could thus influence TMED1 activity. | ||||||